share_log

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Clearmind Medicine | 6-K：外国发行人报告
SEC announcement ·  03/13 16:05
Moomoo AI 已提取核心信息
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has announced the approval of its voluntary delisting from the Canadian Securities Exchange (CSE). The delisting is set to take effect at the close of trading on March 14, 2024. Clearmind Medicine, which is also listed on the NASDAQ under the symbol CMND, cited the low trading volume on the CSE as the primary reason for the delisting, stating that it no longer justifies the expenses and administrative efforts of maintaining a dual listing. The company expects that centralizing its marketplace on the NASDAQ will benefit long-term liquidity and shareholder value. Clearmind assured that its Canadian shareholders would still be able to trade shares through brokers on the NASDAQ, as many Canadian brokers have the capability to trade NASDAQ-listed securities. The company's focus remains on developing treatments for health issues such as alcohol use disorder and it holds a portfolio of fifteen patent families in the field of psychedelic-based compounds.
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has announced the approval of its voluntary delisting from the Canadian Securities Exchange (CSE). The delisting is set to take effect at the close of trading on March 14, 2024. Clearmind Medicine, which is also listed on the NASDAQ under the symbol CMND, cited the low trading volume on the CSE as the primary reason for the delisting, stating that it no longer justifies the expenses and administrative efforts of maintaining a dual listing. The company expects that centralizing its marketplace on the NASDAQ will benefit long-term liquidity and shareholder value. Clearmind assured that its Canadian shareholders would still be able to trade shares through brokers on the NASDAQ, as many Canadian brokers have the capability to trade NASDAQ-listed securities. The company's focus remains on developing treatments for health issues such as alcohol use disorder and it holds a portfolio of fifteen patent families in the field of psychedelic-based compounds.
专门从事迷幻药衍生疗法的生物技术公司Clearmind Medicine Inc. 宣布批准其自愿从加拿大证券交易所（CSE）退市。退市将在2024年3月14日交易收盘时生效。同样在纳斯达克上市，股票代码为CMND的Clearmind Medicine指出，CSE的低交易量是退市的主要原因，并表示它不再为维持双重上市的费用和管理工作辩护。该公司预计，将其市场集中在纳斯达克将有利于长期流动性和股东价值。Clearmind保证，由于许多加拿大经纪商有能力交易纳斯达克上市证券，其加拿大股东仍然能够通过纳斯达克的经纪商交易股票。该公司的重点仍然是开发酒精使用障碍等健康问题的治疗方法，并且在迷幻剂类化合物领域拥有十五个专利家族。
专门从事迷幻药衍生疗法的生物技术公司Clearmind Medicine Inc. 宣布批准其自愿从加拿大证券交易所（CSE）退市。退市将在2024年3月14日交易收盘时生效。同样在纳斯达克上市，股票代码为CMND的Clearmind Medicine指出，CSE的低交易量是退市的主要原因，并表示它不再为维持双重上市的费用和管理工作辩护。该公司预计，将其市场集中在纳斯达克将有利于长期流动性和股东价值。Clearmind保证，由于许多加拿大经纪商有能力交易纳斯达克上市证券，其加拿大股东仍然能够通过纳斯达克的经纪商交易股票。该公司的重点仍然是开发酒精使用障碍等健康问题的治疗方法，并且在迷幻剂类化合物领域拥有十五个专利家族。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息